Risking Women’s Health, While Widening the Door to Techno-Eugenics
By Tina Stevens and Stuart Newman,
CounterPunch
| 09. 26. 2019
In September, California’s legislature passed AB 922, a bill legalizing the payment to women for their eggs for research purposes. Additionally, next year, the California Institute of Regenerative Medicine (CIRM) is expected to return to the voters to secure passage of an initiative that will supply billions of dollars to fund entrepreneurial bioresearch. If Governor Newsom does not veto AB 922, CIRM will have a green light to fund research that will not only jeopardize women’s health through egg extraction but will enable the controversial genetic manipulation of human embryos. (Already, there are bioentrepreneurs who have created genetically engineered human embryos for implantation.)
This human genetic engineering would be massively amplified by vastly expanding the market in women’s eggs, the raw material necessary for the industrialization of human production. (see Stuart A. Newman: “Our Assembly-Line Future? CounterPunch, July 28, 2018). AB 922 and the expected repeat funding of CIRM constitute the leading edge of a juggernaut roaring down the road to techno-eugenics.
When instituted in 2004, CIRM was specifically prohibited from funding research that paid women for eggs. Only...
Related Articles
By Katie Hunt, CNN | 07.30.2025
Scientists are exploring ways to mimic the origins of human life without two fundamental components: sperm and egg.
They are coaxing clusters of stem cells – programmable cells that can transform into many different specialized cell types – to form...
By Ewen Callaway, Nature | 08.04.2025
For months, researchers in a laboratory in Dallas, Texas, worked in secrecy, culturing grey-wolf blood cells and altering the DNA within. The scientists then plucked nuclei from these gene-edited cells and injected them into egg cells from a domestic dog ...
By Kristel Tjandra, Genetic Engineering & Biotechnology News | 07.30.2025
CRISPR has taken the bioengineering world by storm since its first introduction. From treating sickle cell diseases to creating disease-resistant crops, the technology continues to boast success on various fronts. But getting CRISPR experiments right in the lab isn’t simple...
By Arthur Caplan and James Tabery, Scientific American | 07.28.2025
An understandable ethics outcry greeted the June announcement of a software platform that offers aspiring parents “genetic optimization” of their embryos. Touted by Nucleus Genomics’ CEO Kian Sadeghi, the $5,999 service, dubbed “Nucleus Embryo,” promised optimization of...